Edgewise to begin Phase 2 trials for muscular dystrophy drug this year
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company developing drugs to treat muscular dystrophy, reported a $14.7 million net loss in the first quarter of 2022 as it prepares to enter Phase 2 trials for its leading drug candidates. That’s up 15.7% year-over-year.
Edgewise, which is pre-revenue, reported an 11% year-over-year increase in research and development expenses, from $9.1 million to $11.1 million.
The company has $265.8 million in cash and equivalents on hand, which it says can sustain its operations through 2024.
SPONSORED CONTENT
Commercial Solar is a big investment, but not an overwhelming one
Solar offers a significant economic benefit for commercial property owners while also positively impacting the environment and offering a path to compliance for new municipal requirements like Energize Denver. A local, experienced solar installer will help you navigate the complexities of commercial solar to achieve financial success for your project.
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company developing drugs to treat muscular dystrophy, reported a $14.7 million net loss in the first quarter of 2022 as it prepares to enter Phase 2 trials for its leading drug candidates. That’s up 15.7% year-over-year.
Edgewise, which is pre-revenue, reported an 11% year-over-year increase in research and development expenses, from $9.1 million to $11.1 million.
The company has $265.8 million in cash and equivalents on hand, which it says can sustain its operations through 2024.
…THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
